Palisade Bio Inc Stock Price, News & Analysis

Palisade Bio (NASDAQ: PALI) presented positive preclinical data for PALI-2108, their colon-specific PDE4 inhibitor prodrug for treating ulcerative colitis, at Digestive Disease Week 2025. The research demonstrated that PALI-2108 effectively improved clinical parameters of colitis in a dose-dependent manner, showing significant reduction in PDE4B expression and TNF-α suppression compared to standard treatments.

The company showcased results through two posters, with one selected as a Poster of Distinction. Key findings revealed PALI-2108's favorable absorption and bioavailability, with minimal CNS toxicity. The drug is currently in a Phase 1a/b clinical trial, with topline data from the Phase 1a portion expected by the end of May 2025.

Palisade Bio (NASDAQ: PALI) has been selected to present at the 3rd Annual Precision Medicine in Inflammatory Bowel Disease Summit in Boston, MA from May 13-15, 2025. Dr. Joerg Heyer, Head of Translational Science and Medicine, will deliver an oral presentation titled "Improving Patient Subtyping with AI-Driven Insights to Unlock Better Insights into IBD Heterogeneity & Smash the Efficacy Ceiling" on May 13, 2025, from 9:30 AM to 10:00 AM ET.

The presentation falls under the session "Advancing AI-Driven Diagnostics & Enhancing Patient Monitoring to Personalize Treatment Decisions & Improve Long-Term Patient Outcomes." The summit aims to explore advancements in precision medicine strategies and treatment development for IBD patients.

Palisade Bio (NASDAQ: PALI) has successfully completed the Phase 1a portion of its Phase 1a/b study for PALI-2108, a treatment for Ulcerative Colitis (UC). The study included five Single Ascending Dose (SAD) cohorts, four Multiple Ascending Dose (MAD) cohorts, and food effects crossover.

Preliminary results showed promising safety data with no serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs. Several MAD cohorts (15mg-30mg BID) were completed within the expected therapeutic dose range, with minimal adverse events. Only one withdrawal occurred in the highest 50mg twice-daily dosage cohort.

The company is currently screening and dosing patients for the Phase 1b UC cohort, with one subject having completed this portion. Topline data from Phase 1a is expected by May 2025, with complete Phase 1a/b results anticipated in the first half of 2025.

Palisade Bio (NASDAQ: PALI) has initiated dosing in the first Ulcerative Colitis (UC) patient cohort of its ongoing Phase 1a/b study for PALI-2108. The company has completed five single ascending dose (SAD) cohorts and three of four multiple ascending dose (MAD) cohorts, with promising preliminary safety data.

Key highlights include:

• No serious adverse events (SAEs) or treatment-emergent adverse events (TEAEs) related to laboratory values or EKGs
• Majority of TEAEs were mild, with only one withdrawal at highest MAD dose
• Two MAD cohorts completed within expected therapeutic range showed excellent tolerability

The study aims to evaluate safety, tolerability, and pharmacokinetics in both healthy volunteers and UC patients. The trial will analyze various biomarkers including hsCRP, fecal calprotectin, and colonic tissue histological assessments. Topline data is expected in the first half of 2025.

Palisade Bio (NASDAQ: PALI) announced that two abstracts featuring its lead program PALI-2108 for ulcerative colitis treatment have been selected for presentation at Digestive Disease Week (DDW) 2025, scheduled for May 3-6 in San Diego.

The first presentation, focusing on bioinformatic approaches to PALI-2108 treatment in ulcerative colitis, will explore anti-fibrotic efficacy potential with local PDE4 inhibition in intestinal fibrosis. This session is scheduled for May 4, 2025.

The second abstract, recognized as a Poster of Distinction and rated in the top 10% of all AGA abstracts, will present findings on PALI-2108's colon-specific PDE4 inhibitor prodrug properties. The research demonstrates the drug's bioactivation in the colon, its dose-dependent reduction of colon tissue PDE4B, increased c-AMP, and TNF-α suppression in a mouse colitis model. This presentation is scheduled for May 5, 2025.

Palisade Bio (NASDAQ: PALI) has released a Virtual Investor 'What This Means' segment featuring Dr. Joerg Heyer, Head of Translational Science and Medicine. The segment focuses on the company's recent positive preclinical data for their lead product candidate, PALI-2108, which is being developed for the treatment of Ulcerative Colitis (UC).

The preclinical data was previously presented at the 2025 Crohn's and Colitis Congress. Dr. Heyer discusses the implications of these findings for Palisade's UC development program. The virtual segment is now available for viewing, along with other Virtual Investor events.

Palisade Bio (NASDAQ: PALI) has received CAD$1.39 million from Canada's Scientific Research and Experimental Development (SR&ED) Tax Credit Program through its co-development partner, Giiant Pharma. The funds reimburse pre-clinical development costs for PALI-2108, a treatment for Ulcerative Colitis (UC).

The company is currently conducting a Phase 1a/b single-center, double-blind, placebo-controlled study evaluating PALI-2108's safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers, along with an open-label study in UC patients. Topline data from this study is expected in the first half of 2025.

Palisade Bio (Nasdaq: PALI), a clinical-stage biopharmaceutical company focused on developing therapeutics for autoimmune, inflammatory, and fibrotic diseases, has participated in the Virtual Investor 'Top 5 for '25' On-Demand Conference. CEO JD Finley presented the company's top five investment highlights for 2025. The presentation is now available for viewing on the company's website and through the conference platform.

Palisade Bio (NASDAQ: PALI) presented positive preclinical data for PALI-2108, their oral colon-specific PDE4 inhibitor prodrug for ulcerative colitis treatment, at the 2025 Crohn's and Colitis Congress. The drug demonstrated effectiveness in reducing colitis symptoms in mice without CNS toxicity.

Key findings showed that PALI-2108 effectively converts to the active PDE4 inhibitor PALI-0008 in the colon following oral administration in mice, dogs, and humans. The drug outperformed standard treatments in preclinical studies, showing superior potency and target engagement compared to other PDE4 inhibitors.

The company is currently conducting a Phase 1a/b clinical study (NCT06663605) evaluating safety, tolerability, and pharmacokinetics in healthy volunteers and UC patients. Topline data is expected in the first half of 2025.